IFNB1 and myeloid sarcoma: The rationale for early treatment of MS is supported by a study that assessed the differences between patients with MS receiving early versus late IFN-β treatment in terms of the risk of a 1-point progression in EDSS score and the ‘milestone’ EDSS scores of 4.0 and 6.0 [31].